Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.

Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology assays. Block of the human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP). Here we investigated human cardiomyocytes derived from pluripotent (embryonic) stem cells (hESC) as a renewable, scalable, and reproducible system on which to base cardiac safety pharmacology assays. Analyses of extracellular field potentials in hESC-derived cardiomyocytes (hESC-CM) and generation of derivative field potential duration (FPD) values showed dose-dependent responses for 12 cardiac and noncardiac drugs. Serum levels in patients of drugs with known effects on QT interval overlapped with prolonged FPD values derived from hESC-CM, as predicted. We thus propose hESC-CM FPD prolongation as a safety criterion for preclinical evaluation of new drugs in development. This is the first study in which dose responses of such a wide range of compounds on hESC-CM have been generated and shown to be predictive of clinical effects. We propose that assays based on hESC-CM could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for lead optimization and further development of new drugs.

[1]  E. Lindström,et al.  QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. , 2005, The international journal of neuropsychopharmacology.

[2]  CARDIOTOXICITY OF INTRAVENOUS, DOMPERIDONE , 1985, The Lancet.

[3]  Ido Perlman,et al.  Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes , 2004, The Journal of physiology.

[4]  L. Gepstein,et al.  Identification and selection of cardiomyocytes during human embryonic stem cell differentiation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Christine L. Mummery,et al.  Embryonic Stem (es) Cells from Mice and Primates Can Differentiate into Any Cell Type in the Adult Body Stem Cells in Fetal and Adult Hearts Stem-cell-based Therapy and Lessons from the Heart Insight Review , 2022 .

[6]  R. Passier,et al.  Insulin Redirects Differentiation from Cardiogenic Mesoderm and Endoderm to Neuroectoderm in Differentiating Human Embryonic Stem Cells , 2008, Stem cells.

[7]  Hendrik Bonnemeier,et al.  The electrocardiogram of human embryonic stem cell-derived cardiomyocytes. , 2005, Journal of electrocardiology.

[8]  C. Denning,et al.  Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity , 2008 .

[9]  H. Duff,et al.  Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine. , 1989, Molecular pharmacology.

[10]  P. Doevendans,et al.  Patterning the heart, a template for human cardiomyocyte development , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[11]  A. Brown,et al.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.

[12]  K. Olejniczak,et al.  ICH Topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticals , 2002, Fundamental & clinical pharmacology.

[13]  Chris Denning,et al.  Transgenic enrichment of cardiomyocytes from human embryonic stem cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[15]  E. Stanley,et al.  The hESC line Envy expresses high levels of GFP in all differentiated progeny , 2005, Nature Methods.

[16]  L. Fauchier,et al.  Effect of verapamil on QT interval dynamicity. , 1999, The American journal of cardiology.

[17]  D. Roden,et al.  Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. , 1987, The Journal of pharmacology and experimental therapeutics.

[18]  R. Passier,et al.  Differentiation of human embryonic stem cells to cardiomyocytes by coculture with endoderm in serum-free medium. , 2007, Current protocols in stem cell biology.

[19]  W. Crumb,et al.  Quinidine interactions with human atrial potassium channels: developmental aspects. , 1998, Circulation research.

[20]  S. Liu,et al.  Inhibition of L-type Ca2+ channel current in rat ventricular myocytes by terfenadine. , 1997, Circulation research.

[21]  Robert Passier,et al.  Increased Cardiomyocyte Differentiation from Human Embryonic Stem Cells in Serum‐Free Cultures , 2005, Stem cells.

[22]  Robert Passier,et al.  Cardiomyocyte differentiation from embryonic and adult stem cells. , 2005, Current opinion in biotechnology.

[23]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[24]  Icilio Cavero,et al.  ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis , 2005, Expert opinion on drug safety.

[25]  Rene Spijker,et al.  Differentiation of Human Embryonic Stem Cells to Cardiomyocytes: Role of Coculture With Visceral Endoderm-Like Cells , 2003, Circulation.

[26]  RenéCardinal,et al.  Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders , 2000 .

[27]  L. Hondeghem,et al.  Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea‐pig papillary muscle , 1988, British journal of pharmacology.

[28]  L. V. Van Laake,et al.  Human embryonic stem cells: genetic manipulation on the way to cardiac cell therapies. , 2005, Reproductive toxicology.

[29]  Benjamin A Lipsky,et al.  Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. , 1999, Clinical therapeutics.

[30]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[31]  B. Darpö,et al.  Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .

[32]  Stanley Nattel,et al.  Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.

[33]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[34]  Arthur J Moss,et al.  Long QT syndrome: from channels to cardiac arrhythmias. , 2005, The Journal of clinical investigation.

[35]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[36]  Shingo Suzuki,et al.  Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. , 2004, European journal of pharmacology.

[37]  A. Colman,et al.  Highly enriched cardiomyocytes from human embryonic stem cells. , 2008, Cytotherapy.

[38]  S. Bryant,et al.  Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. , 2007, Journal of pharmacological and toxicological methods.

[39]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[40]  C. Mummery,et al.  Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. , 2008, Differentiation; research in biological diversity.